

Brightseed and ofi announce partnership to explore health benefits in popular spices

13 January 2022 | News

Brightseed and ofi announce partnership to explore health benefits in popular spices



Brightseed will use its award-winning Forager® artificial intelligence platform to seek to identify complex molecular structures and novel compounds in these spice categories.

Brightseed and ofi announce partnership to explore health benefits in popular spices

Through a partnership with Brightseed, a biosciences data company and a World Economic Forum Technology Pioneer, olam food ingredients (“ofi”), a global leader in naturally good food & beverage ingredients, hopes to learn which varieties deliver the highest levels of bioactives. ofi’s innovation team working at ingredient excellence centers in Fresno, California and Vietnam hope to discover exactly what health benefits exist in its U.S. garlic and global black pepper varieties.

Brightseed will use its award-winning Forager® artificial intelligence platform to seek to identify complex molecular structures and novel compounds in these spice categories. Forager® seeks to pinpoint the specific mechanisms of plant bioactives that likely correlate to a direct health benefit, thereby decoding the health impact of plant-based bioactive compounds and increasing the scientific understanding of these spices’ qualities.

Medical research has shown that black pepper produces piperine, a bioactive and antioxidant that has the potential to inhibit tumor growth and enhance the bioavailability of some therapeutic drugs. Medical research has also shown that garlic contains strong beneficial properties that may prevent common chronic disease states and other pathologies. Forager® will analyze and seek to identify how different regions, cultivars, growing conditions, and processing methods impact phytochemical expression and bioactive potency across multiple areas of human health for ofi’s black pepper estates and its U.S.-based garlic sources. All of Forager’s® discoveries undergo in vitro validation and enable a de-risked clinical trial process for innovation.